ONCS - OncoSec Medical Incorporated

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.57
+0.01 (+0.64%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.56
Open1.57
Bid0.00 x 4000
Ask0.00 x 800
Day's Range1.53 - 1.58
52 Week Range0.88 - 2.95
Volume248,317
Avg. Volume1,197,175
Market Cap80.827M
Beta2.40
PE Ratio (TTM)N/A
EPS (TTM)-1.09
Earnings DateDec 6, 2017 - Dec 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer
    PR Newswire16 days ago

    OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer

    SAN DIEGO , May 8, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, has entered a clinical trial collaboration and supply ...

  • OncoSec to Present at Eighth Annual BioNJ BioPartnering Conference
    PR Newswire21 days ago

    OncoSec to Present at Eighth Annual BioNJ BioPartnering Conference

    SAN DIEGO , May 3, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor , Chief Executive ...

  • ACCESSWIRE21 days ago

    Why the Prestigious Mayo Clinic is a 10% Holder of This Undiscovered Public Company

    Robert Duggan's very public success with PCYC from $1 to $260 is a recent example. The Mayo Clinic is one of the most prestigious healthcare systems globally, and this institute is a 10% holder of stock in NeuroOne (NMTC), a company that develops technology for use in neurologic conditions. The company is completely undiscovered by public investors yet has a few big events coming up in the next 12 months, including a filing with the FDA (food and drug administration) for the approval of their first medical device.

  • OncoSec Announces PISCES/KEYNOTE-695 Trial-in-Progress Poster Presentation at Upcoming ASCO 2018 Annual Meeting
    PR Newswire28 days ago

    OncoSec Announces PISCES/KEYNOTE-695 Trial-in-Progress Poster Presentation at Upcoming ASCO 2018 Annual Meeting

    SAN DIEGO , April 26, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, will present a trial-in-progress poster presentation  ...

  • ACCESSWIRElast month

    GVC Capital and Trickle Research Announce Presenter Schedule for Rocky Mountain MicroCap Conference II in Denver on April 24, 2018

    DENVER, CO / ACCESSWIRE / April 20, 2018 / GVC Capital LLC ("GVC") and Dave Lavigne at Trickle Research LLC ("Trickle Research") will host the Rocky Mountain MicroCap Conference II ...

  • OncoSec Provides Highlights from Research Reception at AACR Annual Meeting 2018
    PR Newswirelast month

    OncoSec Provides Highlights from Research Reception at AACR Annual Meeting 2018

    SAN DIEGO , April 16, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today provided highlights from its Research Reception ...

  • OncoSec to Host Research Reception During the 2018 American Association of Cancer Research Annual Meeting
    PR Newswire2 months ago

    OncoSec to Host Research Reception During the 2018 American Association of Cancer Research Annual Meeting

    Clinicians to Provide Updates on OncoSec's Intratumoral IL-12 Program in Triple Negative Breast Cancer (TNBC) and Melanoma SAN DIEGO , April 3, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) ...

  • OncoSec Announces Strategic Relocation Of Office And Laboratories
    PR Newswire2 months ago

    OncoSec Announces Strategic Relocation Of Office And Laboratories

    SAN DIEGO, March 20, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (ONCS), a company developing intratumoral cancer immunotherapies, today announced a strategic relocation of its office and lab in San Diego that is expected to provide immediate and significant cost-savings of approximately $65,000 per month. "I joined OncoSec with the goal of leading the Company toward the successful completion of its Phase 2b registration-directed trial, PISCES/KEYNOTE-695, with data anticipated this year and a potential submission to the U.S. Food and Drug Administration in 2019," stated Daniel J. O'Connor, CEO of OncoSec. "By relocating our office and lab, we trade a $14 million liability for a $2 million liability and generated an immediate cash savings of approximately $65,000 per month in rent and associated expenses.

  • OncoSec To Present At The Oppenheimer's 28th Annual Healthcare Conference
    PR Newswire2 months ago

    OncoSec To Present At The Oppenheimer's 28th Annual Healthcare Conference

    SAN DIEGO , March 16, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor , Chief ...

  • OncoSec's Intratumoral IL-12 In Metastatic Triple Negative Breast Cancer (TNBC) Selected For Oral Poster Presentation At The American Association For Cancer Research (AACR) Annual Meeting 2018
    PR Newswire2 months ago

    OncoSec's Intratumoral IL-12 In Metastatic Triple Negative Breast Cancer (TNBC) Selected For Oral Poster Presentation At The American Association For Cancer Research (AACR) Annual Meeting 2018

    SAN DIEGO , March 15, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that clinical and immunological data ...

  • OncoSec Announces Publication In Nature Gene Therapy Demonstrating Efficacy Of IL-12 Intratumoral Gene Electrotransfer
    PR Newswire2 months ago

    OncoSec Announces Publication In Nature Gene Therapy Demonstrating Efficacy Of IL-12 Intratumoral Gene Electrotransfer

    Research Spotlights OncoSec's Next Generation Electroporation (EP) Platform SAN DIEGO , March 12, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral ...

  • OncoSec Medical Incorporated Announces Closing of $23.0 Million Public Offering of Common Stock
    PR Newswire4 months ago

    OncoSec Medical Incorporated Announces Closing of $23.0 Million Public Offering of Common Stock

    SAN DIEGO, Feb. 6, 2018 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (ONCS), a biotechnology company focused on designing, developing and commercializing innovative immunotherapies and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 15,333,334 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,000,000 additional shares, at the public offering price of $1.50 per share. The gross proceeds from the offering, including the exercise of the option to purchase additional shares, were approximately $23 million, before deducting underwriting discounts and commissions and estimated offering expenses paid by OncoSec.

  • OncoSec Medical Incorporated Prices $20.0 Million Public Offering of Common Stock
    PR Newswire4 months ago

    OncoSec Medical Incorporated Prices $20.0 Million Public Offering of Common Stock

    SAN DIEGO, Feb. 1, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (ONCS), a biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a price of $1.50 per share, with expected gross proceeds of approximately $20 million, before deducting underwriting discounts and commissions and estimated offering expenses paid by OncoSec. In addition, OncoSec has granted the underwriters a 30-day option to purchase up to an additional 2,000,000 shares of common stock on the same terms and conditions. Cantor Fitzgerald & Co. is also acting as a book runner.

  • OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock
    PR Newswire4 months ago

    OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock

    SAN DIEGO, Jan. 31, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (ONCS), a biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Piper Jaffray & Co. is acting as lead book-running manager for the offering.  Cantor Fitzgerald & Co. is also acting as a book runner.

  • Benzinga4 months ago

    Avacta, OncoSec to Collaborate to Combine Avacta's Affimer Protein Platform with OncoSec's Gene Delivery Technology ImmunoPulse

    Avacta Group plc (OTC:AVCTF) and OncoSec Medical Incorporated (NASDAQ: ONCS ), are pleased to announce they have entered into a research collaboration to combine Avacta's Affimer protein platform with ...

  • OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study
    PR Newswire4 months ago

    OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study

    SAN DIEGO , Jan. 18, 2018 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced ...

  • OncoSec Appoints Veteran Biopharma Executive Gregory T. Mayes To Board Of Directors
    PR Newswire4 months ago

    OncoSec Appoints Veteran Biopharma Executive Gregory T. Mayes To Board Of Directors

    SAN DIEGO, Jan. 16, 2018 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec" or the "Company") (ONCS), a company developing intratumoral cancer immunotherapies, today announced the appointment of Gregory T. Mayes to its board of directors. Mr. Mayes is President, Chief Executive Officer and Founder of Engage Therapeutics, and brings over 20 years of experience as a biopharmaceutical executive with an extensive network in the life sciences field to OncoSec's board of directors. The Company's Board appointed him on Friday, January 12, 2018.

  • OncoSec Provides 2018 Business Outlook
    PR Newswire5 months ago

    OncoSec Provides 2018 Business Outlook

    Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse® IL-12 in combination with KEYTRUDA® (pembrolizumab) Present preliminary data from PISCES/KEYNOTE-695 at a medical meeting ...

  • OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab
    PR Newswire5 months ago

    OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab

    SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec" or the "Company") (ONCS), a company developing intratumoral cancer immunotherapies, today announced the initiation of patient dosing in PISCES/KEYNOTE-695, the company's global, multi-center, registration-directed open-label Phase 2b clinical trial. The trial will evaluate the combination of ImmunoPulse® IL-12 (intratumoral pIL-12 [tavokinogene telseplasmid or "tavo"] with electroporation), and pembrolizumab in patients with unresectable metastatic melanoma who have progressed or are progressing on an anti-PD-1 therapy. Based on the encouraging data we presented at SITC, we believe the combination of ImmunoPulse IL-12 and pembrolizumab may offer a differentiated approach to reshaping the tumor microenvironment by converting immunologically cold tumors to hot," said Sharron Gargosky, Chief Clinical and Regulatory Officer of OncoSec.

  • OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
    PR Newswire6 months ago

    OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer

    SAN DIEGO , Dec. 5, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced the promotion of Christopher ...

  • OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform
    PR Newswire6 months ago

    OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform

    The first patent, JP06174632, encompasses a device for post-resection electroporation ("EP") delivery of an agent (including nucleic acids) to prevent recurrence of resected tumors and expires in 2030. The second patent, US 9,610,634, adds to the ImmunoPulse® IL-12 portfolio, and includes coverage for reducing tumor angiogenesis while increasing T cell proliferation by the EP delivery of plasmid encoded IL-12.  The second patent expires in 2025.

  • OncoSec Receives $9.3 Million Warrant Exercise
    PR Newswire6 months ago

    OncoSec Receives $9.3 Million Warrant Exercise

    SAN DIEGO, Nov. 13, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it has entered into entered into a Warrant Exercise Agreement with certain holders of outstanding warrants to purchase up to an aggregate of 5,509,642 shares of the Company's common stock, at its stated exercise price of $1.69 per share. As a result, the Company received gross proceeds of approximately $9.3 million from the exercise of the warrants. The Company expects to use the proceeds for working capital and general corporate purposes, including primarily for its PISCES/KEYNOTE-695 clinical trial and for other clinical and research and development activities.

  • SmarterAnalyst6 months ago

    H.C. Wainwright Upbeat on OncoSec Medical Following Updated Phase 2 Data

    OncoSec Medical (NASDAQ:ONCS) just hit clinical trial results out of the park in the melanoma arena, with a Phase 2 combination trial that has H.C. Wainwright analyst Ram Selvaraju looking ahead to better clinical outcomes in patients not responsive to solely anti-PD-1 therapy.

  • ACCESSWIRE6 months ago

    Corporate News Blog - OncoSec Medical Reports Positive Updated Follow-Up Data from Phase-2 Trial of ImmunoPulse IL-12 in Combination with Pembrolizumab

    Research Desk Line-up: Radius Health Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 10, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...